Focus on the prophylaxis, epidemiology and therapy of methicillin-resistant Staphylococcus aureus surgical site infections and a position paper on associated risk factors: the perspective of an Italian group of surgeons

Table 7 The main characteristics of anti MRSA drugs used for SSIs

Antibiotic	Battericidal activity/Pharmacodynamic/anti-biofilm activity	Route of administration	Doses	Adverse events	Interaction	Cost (70 kg)
Teicoplanin	Bactericidal with low MIC/time dependent/none	iv im	7-10 mg/Kg die, loading dose	Renal toxicicty	None	50–70 E/die
Vancomycin	Bactericidal with low MIC/time dependent/none	Iv	1 g x 2 die 500 mg x 4 die	Renal toxicicty	Other nephrotoxic drugs	5 E/die
Daptomycin	Bactericidal/concentration dependent/yes	Iv	4–6 mg/kg	Tossicità muscolare	Statine	80–120 E/die
Linezolid	Bacteriostatic/time dependent/none	Iv/oral	1200 mg die	Bome marrow toxicity, neuropathy, serotoninergic syndrome	SSRI	120 E/die
Tigecycline	Bacteriostatic/time dependent/partial	Iv	50 mg x 2 die; 100 mg loading dose	Nausea, vomit, pancreatitis	None	120 E/die
Ceftaroline	Bactericidal/time dependent/none	Iv	600 mg x 2 die	rash	None	96 E/die
Dalbavancin	Bactericidal/concentration dependent/partial (in association with rifampin)	Iv	1000 mg giorno 1, 500 mg giorno 7	No	None	NA
Cotrimoxazole	Bactericidal/time dependent/none	Iv, oral	800/160 mg 3 times a dai	anemia	None	15 E/die
Rifampin	Bactericidal/time dependent/yes	Iv/oral	600 mg once a day	Liver toxicity	Several	6 E/die

ISSN: 1749-7922